Brief: Plus Therapeutics Announces FDA Clearance Of Its Investigational New Drug Application
25/06/2025 12:33
June 25 (Reuters) - Plus Therapeutics Inc PSTV.O: PLUS THERAPEUTICS ANNOUNCES FDA CLEARANCE OF ITS INVESTIGATIONAL NEW DRUG APPLICATION USING REYOBIQTM FOR THE TREATMENT OF CHILDHOOD BRAIN CANCER Source text: ID:nGNX70WXjc Further company coverage: PSTV.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cerenome
See all newsBrief: Cerenome Secures In-Network Agreement With Florida Blue For Cnside® Csf Tumor Cell Enumeration And Molecular Profile Tests
Plus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Cerenome Secures In-Network Agreement With Health Care Service Corporation
Plus Therapeutics Inc expected to post a loss of 91 cents a share - Earnings Preview
Brief: Plus Therapeutics Secures Regional Coverage Agreement With Medical Mutual For CNSide Cerebrospinal Fluid Assay For Metastatic CNS Cancer